Jubilant Pharmova Management
Management criteria checks 2/4
Jubilant Pharmova's CEO is Priyavrat Bhartia, appointed in Jun 2023, has a tenure of 1.58 years. total yearly compensation is ₹67.47M, comprised of 37.1% salary and 62.9% bonuses, including company stock and options. directly owns 0.88% of the company’s shares, worth ₹1.52B. The average tenure of the management team and the board of directors is 2 years and 7 years respectively.
Key information
Priyavrat Bhartia
Chief executive officer
₹67.5m
Total compensation
| CEO salary percentage | 37.1% |
| CEO tenure | 1.6yrs |
| CEO ownership | 0.9% |
| Management average tenure | 2yrs |
| Board average tenure | 7yrs |
Recent management updates
Recent updates
Insufficient Growth At Jubilant Pharmova Limited (NSE:JUBLPHARMA) Hampers Share Price
Dec 21
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Nov 15A Look At The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Oct 27Jubilant Pharmova Limited (NSE:JUBLPHARMA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 24Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Jul 13Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth
Dec 23These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
May 11Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00
Aug 01Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?
Jun 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Mar 22Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Feb 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Dec 20Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year
Sep 15Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly
Aug 21Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook
Jun 08An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued
May 25Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts
Feb 10Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)
Feb 08
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹6b |
| Jun 30 2024 | n/a | n/a | ₹6b |
| Mar 31 2024 | ₹67m | ₹25m | ₹771m |
Compensation vs Market: Priyavrat's total compensation ($USD786.87K) is above average for companies of similar size in the Indian market ($USD478.11K).
Compensation vs Earnings: Insufficient data to compare Priyavrat's compensation with company performance.
CEO
Priyavrat Bhartia (48 yo)
1.6yrs
Tenure
₹67,466,997
Compensation
Mr. Priyavrat Bhartia, MBA, is the Non-Executive Chairman at Digicontent Limited and has been its Non-Executive Director since August 14, 2017. He has been Non-Executive Director of Hindustan Media Venture...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Director | 1.6yrs | ₹67.47m | 0.88% ₹ 1.5b | |
| Joint MD & Director | 1.6yrs | ₹67.47m | no data | |
| Group CFO & Whole-Time Director | 1.7yrs | ₹44.78m | no data | |
| Executive VP of Group Accounts | no data | no data | no data | |
| Group Chief Digital & Information Officer | no data | ₹16.53m | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Executive VP & Head of Legal | 10.2yrs | ₹3.34m | no data | |
| Company Secretary & Compliance Officer | 2.4yrs | ₹6.86m | no data | |
| Group Chief Human Resources Officer | 2yrs | no data | no data | |
| Advisor | 4.8yrs | ₹67.29m | no data | |
| Senior Vice President of Corporate Affairs | no data | no data | no data | |
| President of Life Science Chemicals | no data | ₹19.34m | no data |
2.0yrs
Average Tenure
55yo
Average Age
Experienced Management: JUBLPHARMA's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Director | 7.7yrs | ₹67.47m | 0.88% ₹ 1.5b | |
| Joint MD & Director | 7.7yrs | ₹67.47m | no data | |
| Group CFO & Whole-Time Director | 3.8yrs | ₹44.78m | no data | |
| Additional Director & Whole-time Director | less than a year | no data | no data | |
| Chairman | 46.6yrs | no data | 0.085% ₹ 145.5m | |
| Independent Non-Executive Director | 7.7yrs | ₹2.59m | no data | |
| Independent Non-Executive Director | 6.3yrs | ₹2.01m | no data | |
| Independent Director | less than a year | no data | no data | |
| Co-Chairman | 41.2yrs | ₹124.06m | 0.23% ₹ 402.3m | |
| Independent Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 7.7yrs | ₹2.53m | no data | |
| Additional Independent Non-Executive Director | 1.8yrs | ₹2.23m | no data |
7.0yrs
Average Tenure
66.5yo
Average Age
Experienced Board: JUBLPHARMA's board of directors are considered experienced (7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 04:52 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jubilant Pharmova Limited is covered by 31 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harith Ahamed | Avendus Spark |
| Deepak Khetan | Axis Capital Limited |
| Gaurav Chugh | Batlivala & Karani Securities India Pvt. Ltd. |